Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-10-31 Transaction in Own Shar…
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司股东减持股份计划公告
Transaction in Own Shares Classification · 95% confidence The document is titled as a "股东减持股份计划公告" which translates to "Shareholder Share Reduction Plan Announcement." It details a major shareholder's plan to reduce their holdings, including specific share quantities, percentages, timing, and compliance with regulatory requirements. The content focuses on the shareholder's planned sale of shares, past reductions, and risk disclosures related to the share reduction. There is no financial statement, earnings data, or management discussion of financial results. The document is an announcement about a shareholder's planned reduction of shares, which fits the category of Transaction in Own Shares (POS). The document length is under 5,000 characters and is a detailed announcement rather than a brief notice, so it is not a simple report publication announcement or regulatory filing. Therefore, the appropriate classification is POS with high confidence.
2022-10-31 Chinese
长春百克生物科技股份公司2022年第三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2022 Third Quarter Report" of Changchun Baike Biotechnology Co., Ltd. It contains detailed financial data for the third quarter, including income, net profit, cash flow, earnings per share, and balance sheet items as of September 30, 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. There is no indication that this is merely an announcement or a certification. The length and content confirm it is a full interim/quarterly financial report. Q3 2022
2022-10-27 Chinese
北京植德律师事务所关于长春百克生物科技股份公司2022年限制性股票激励计划首次授予事项的法律意见书
Legal Proceedings Report Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the first grant of a 2022 restricted stock incentive plan by Changchun Baike Biotechnology Co., Ltd. It details the approval and authorization process, the grant date, the recipients and quantities of restricted stock, and the conditions for the grant. The document is a standalone legal opinion related to a stock incentive plan, not a financial report, earnings release, or regulatory announcement. It does not contain financial statements or earnings data, nor is it a notice or announcement of voting results or capital changes. It is a legal proceeding related document providing a formal legal opinion on the stock incentive plan grant. Therefore, it fits best under the category of Legal Proceedings Report (LTR). The document length is 4422 characters, which is substantive and contains detailed legal analysis, not a brief announcement or certification. Hence, the classification is LTR with high confidence.
2022-10-17 Chinese
长春百克生物科技股份公司关于2022年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告
Regulatory Filings Classification · 95% confidence The document is a self-inspection report regarding insider trading activities related to a 2022 restricted stock incentive plan. It details the investigation of stock transactions by insiders during a specific period and concludes no misuse of insider information. The document is a regulatory announcement about insider trading compliance and internal controls, not a financial report, earnings release, or management report. It does not fit categories like Annual Report, Earnings Release, or Management Reports. It is a regulatory disclosure related to compliance and insider trading, best classified under Regulatory Filings (RNS). The document length is short (1846 characters), and it is a standalone announcement, not a report publication announcement or certification letter. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-10-17 Chinese
长春百克生物科技股份公司关于向激励对象首次授予限制性股票的公告
Share Issue/Capital Change Classification · 95% confidence The document is a detailed announcement regarding the initial grant of restricted stock to incentive recipients by Changchun Baike Biotechnology Co., Ltd. It includes specifics such as the grant date, number of shares, pricing, eligibility criteria, legal and financial advisor opinions, and compliance with regulatory requirements. The content focuses on the company's stock incentive plan and the approval process, including board and supervisory committee opinions. This type of document is a formal announcement about a share-based incentive plan and the issuance of restricted stock to employees and management, which is a capital change event. It is not a financial report, earnings release, or management discussion. It is also not a proxy statement or voting result announcement. The document is best classified as a Share Issue/Capital Change announcement (SHA) because it details the issuance of new shares under a stock incentive plan.
2022-10-17 Chinese
长春百克生物科技股份公司第五届监事会第七次会议决议的公告
Regulatory Filings Classification · 95% confidence The document is an announcement of a supervisory board meeting resolution regarding the initial grant of restricted stock under a stock incentive plan. It includes details about the meeting date, attendance, and voting results. The content focuses on governance and approval of stock incentive matters, not on financial results or detailed reports. The document length is short (1103 characters) and it references another announcement for more details. This fits best with a Regulatory Filings (RNS) category as it is a formal regulatory announcement about governance and stock incentive approval, not a full report or financial statement.
2022-10-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.